Abstract
This paper identifies the recruitment strategies and human immunodeficiency virus (HIV) risk behaviors of at-risk women in an HIV vaccine preparredness study in New York City, assesses how these behaviors changed over time, and draws implications for women's involvement in HIV vaccine efficacy trials. Noninjecting HIV-1 ngative women (N=89) were recruited into an HIV vaccine preparedness study. An observational cohort study design was used. Women were recruited from clinics and community-based organizations (40%), through other study participants (24%), through newspaper advertisements (20%), and through street outreach (16%). Most women who refused (72%) also came from clinics and agencies. Retention after 12 months was 67%; after 18 months, it was 62%. The proportion of women reporting unprotected vaginal sex in the previous 3 months was 85% at baseline and declined to 70% after 12 months (P<.05). There have been no seroconversions detected. Recruitment efforts to include at-risk women in HIV vaccine efficacytrials must be diverse and actively involve community agencies. Successfully retaining these cohorts over time and detecting a high enough HIV seroincidence rate present ongoing challenges that will need to be addressed to ensure women's involvement in future trials in the US
Key words: Efficacy Trials, HIV, Vaccine Preparedness Study, Women
Full Text
The Full Text of this article is available as a PDF (647.9 KB).
References
- 1.Wortley PM, Fleming PL. AIDS in women in the United States. JAMA. 1997;278(11):911–916. doi: 10.1001/jama.278.11.911. [DOI] [PubMed] [Google Scholar]
- 2.Graham BS, Wright PF. Candidate AIDS vaccines. N Engl J Med. 1995;333:1331–1339. doi: 10.1056/NEJM199511163332007. [DOI] [PubMed] [Google Scholar]
- 3.Bloom BR. A perspective on AIDS vaccines. Science. 1996;272:1888–1890. doi: 10.1126/science.272.5270.1888. [DOI] [PubMed] [Google Scholar]
- 4.Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12:785–793. doi: 10.1097/00002030-199807000-00015. [DOI] [PubMed] [Google Scholar]
- 5.Chesney MA, Lurie P, Coates TJ. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9:30–35. [PubMed] [Google Scholar]
- 6.Koblin BA, Avrett S, Taylor PE, Stevens CE. Willingness to participate in HIV-1 vaccine efficacy trials and the effect of media events among gay and bisexual men in New York City: Project ACHIEVE. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:165–171. doi: 10.1097/00042560-199706010-00011. [DOI] [PubMed] [Google Scholar]
- 7.Hunt JR, White E. Retaining and tracking cohort study members. Epidemiol Rev. 1998;20(1):57–70. doi: 10.1093/oxfordjournals.epirev.a017972. [DOI] [PubMed] [Google Scholar]
- 8.Mausner JS, Bahn AK. Epidemiology: An Introductory Text. Philadelphia, PA: W. B. Saunders and Company; 1985. [Google Scholar]
- 9.Worth D. Women at high risk of HIV infection: behavioral, prevention and intervention aspects. In: Ostrow DG, editor. Behavioral Aspects of AIDS. New York: Plenum; 1990. pp. 101–119. [Google Scholar]
- 10.Wright J. Asking for community assistance to prepare for large HIV vaccine trials in San Francisco. Paper presented at:Twelfth World AIDS Conference; June 28–July 3, 1998; Geneva, Switzerland. Abstract 24215.
- 11.Auerbach JD, Figert AE. Women's health research: public policy and sociology.J Health Soc Behav. 1995;(spec. no.); 115–131. [PubMed]
- 12.El-Bassel N, Schilling RF. Fifteen-month follow-up of women methadone patients taught skills to reduce heterosexual HIV transmission. Public Health Rep. 1992;107:500–504. [PMC free article] [PubMed] [Google Scholar]
- 13.El-Sadr W, Capps L. The challenge of minority recruitment in clinical trials for AIDS. JAMA. 1992;267(7):954–957. doi: 10.1001/jama.267.7.954. [DOI] [PubMed] [Google Scholar]
- 14.Brown-Peterside P, Smith C, Affleck P, Doherty-Iddings P, Harrison C, Clark C. Enabling women to Participate in HIV vaccine efficacy trials: lessons learned from a US vaccine preparedness study. Paper presented at:Twelfth World AIDS Conference; June 28–July 3, 1998; Geneva, Switzerland. Abstract 33215.
- 15.Osborn JE. The rocky road to an AIDS vaccine. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9:26–29. [PubMed] [Google Scholar]
- 16.Seage GE III, Metzger D, Holte S, Buchbinder S, Koblin B, Celum C. Feasibility of conducting HIV-1 vaccine trials in the United States: recruitment, retention and HIV-1 seroincidence from the HIV Network for Prevention Trials (HIVNET) Vaccine Preparedness Study (VPS). Paper presented at:Twelfth World AIDS Conference; June 28–July 3, 1998; Geneva, Switzerland. Abstract 43543.
- 17.Exner TM, Seal DW, Ehrhardt AA. A review of HIV interventions for at-risk women. AIDS. 1997;2(1):93–124. [Google Scholar]
- 18.Stein ZA. HIV prevention: the need for methods women can use. Am J Public Health. 1990;80:460–462. doi: 10.2105/ajph.80.4.460. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Birmingham K. HIV Vaccines—and the winner is ... Nat Med. 1998;4(7):753–753. doi: 10.1038/nm0798-753. [DOI] [PubMed] [Google Scholar]